Abstract | INTRODUCTION: PATIENTS AND METHODS: Eligibility included histologically or cytologically proven SCLC, no previous systemic chemotherapy, performance status of 0 to 2, and age ≥ 70 years. Patients received amrubicin (70-74 years old, 40-45 mg/m(2); ≥ 75 years old, 40 mg/m(2)) intravenously on days 1 to 3 every 3 weeks for 4 to 6 cycles or carboplatin (area under the curve of 5 intravenously on day 1) and etoposide (80 mg/m(2) intravenously on days 1 to 3) every 3 weeks for 4 to 6 cycles. RESULTS: The target number of patients was 130 with 65 in each arm. However, the study was terminated early owing to 3 treatment-related deaths in the amrubicin arm, and only 62 patients (median age, 76 years; range, 70-88 years) were enrolled. The characteristics of the patients in the amrubicin and carboplatin/ etoposide arms did not differ significantly. Overall survival, time to progression, and objective response rate were 10.9 vs. 11.3 months (P = .7353), 4.7 vs. 4.4 months, and 74.2% (23 of 31) vs. 60.0% (18 of 30), respectively, and quality of life showed no significant difference between the 2 arms. Higher incidences of febrile neutropenia and interstitial lung disease of grade 3 or worse occurred with amrubicin (34.4% vs. 3.3% and 12.5% vs. 0%, respectively). CONCLUSION: These results indicate that amrubicin monotherapy at 40 to 45 mg/m(2) is toxic and intolerable in elderly Japanese patients with ED-SCLC.
|
Authors | Ikuo Sekine, Hiroaki Okamoto, Takeshi Horai, Kazuhiko Nakagawa, Hironobu Ohmatsu, Akira Yokoyama, Nobuyuki Katakami, Masahiko Shibuya, Nagahiro Saijo, Masahiro Fukuoka |
Journal | Clinical lung cancer
(Clin Lung Cancer)
Vol. 15
Issue 2
Pg. 96-102
(Mar 2014)
ISSN: 1938-0690 [Electronic] United States |
PMID | 24361248
(Publication Type: Clinical Trial, Phase III, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Copyright | Copyright © 2014 Elsevier Inc. All rights reserved. |
Chemical References |
- Anthracyclines
- Etoposide
- amrubicin
- Carboplatin
|
Topics |
- Aged
- Anthracyclines
(administration & dosage)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Brain Neoplasms
(drug therapy, mortality, secondary)
- Carboplatin
(administration & dosage)
- Etoposide
(administration & dosage)
- Female
- Follow-Up Studies
- Humans
- Lung Neoplasms
(drug therapy, mortality, pathology)
- Male
- Neoplasm Staging
- Prognosis
- Quality of Life
- Small Cell Lung Carcinoma
(drug therapy, mortality, pathology)
- Survival Rate
|